Sodium channel blocker. Prepn: E. J. Cragoe, Jr., BE 639386; idem, US 3313813 (1964, 1967 both to Merck & Co.). NMR study on tautomerism and conformation: R. L. Smith et al., J. Am. Chem. Soc. 101, 191 (1979). Determn by isopotential fluorimetry: J. A. Murillo Pulgarín et al., Analyst 122, 247 (1997). Pharmacology: Baer et al., J. Pharmacol. Exp. Ther. 157, 472 (1967); Baba et al., Clin. Pharmacol. Ther. 9, 318 (1968); Lant et al., ibid. 10, 50 (1969). Metabolism: Weiss et al., ibid. 401. Clinical evaluation in cystic fibrosis: M. R. Knowles et al., N. Engl. J. Med. 322, 1189 (1990); in combination with uridine 5′-triphosphate, q.v.: W. D. Bennett et al., Am. J. Respir. Crit. Care Med. 153, 1796 (1996). Reviews: H. L. Macfie et al., Drug Intell. Clin. Pharm. 15, 94-98 (1981); D. E. Hyams, Int. Congr. Symp. Ser. - R. Soc. Med. 44, 65-73 (1981). Comprehensive description of hydrochloride: D. J. Mazzo, Anal. Profiles Drug Subs. 15, 1-34 (1986). Review of mechanism of action: T. R. Kleyman, et al., Semin. Nephrol. 19, 524-532 (1999).
Diuretic.
Diuretic